Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Persistent or Recurrent Cervical Cancer
NCT02257528Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2015
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in Cervical Cancer (CC), sponsored by National Cancer Institute. Started May 2015; status: active, not recruiting.
02
Drugs
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT02257528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02257528.